🇺🇸 FDA

Company profile · Sponsor

Perspective

Perspective Therapeutics

CATX · NYSE pharma SEATTLE, WA, USA
Pipeline
6
Drugs
0
Patents
1

Quick answer

Perspective (CATX) is a pharma company. headquartered in SEATTLE, WA, USA. listed on NYSE. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 1 patent to this profile..

Company facts

Ticker CATX
Exchange NYSE
Company type pharma
Headquarters SEATTLE, WA, USA
SEC CIK 0000728387

Pipeline (6)

Search pipeline →

  1. [203Pb]Pb-PSV359

    Perspective

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  2. [203Pb]VMT-α-NET

    Perspective

    Neuroendocrine Tumors Unresectable

    phase 2 small molecule active

    1 trial

  3. [203Pb]VMT01

    Perspective

    Recurrent Melanoma (Skin)

    phase 2 small molecule active

    1 trial

  4. [203Pb]VMT-α-NET

    Perspective

    Neuroendocrine Tumor Grade 2

    phase 1 small molecule active

    1 trial

  5. [203Pb]VMT01

    Perspective

    Melanoma (Skin)

    phase 1 small molecule completed

    1 trial

  6. [212Pb] VMT-α-NET

    Perspective

    Neuroendocrine Tumors

    phase 1 small molecule active

    1 trial

Patents (1)

Search patents →

  1. US 10646435

    Pasty bio-adhesive sustained release compositions

    Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Perspective?

Perspective (CATX) is a pharma company. headquartered in SEATTLE, WA, USA. listed on NYSE. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 1 patent to this profile..

What pipeline programs does Perspective sponsor?

We track 6 ClinicalTrials.gov-linked programs for Perspective, including [203Pb]Pb-PSV359 and 5 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Perspective company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.